Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term effects of Sativex on cognition, mood and spasticity in multiple sclerosis
2011-000926-31Phase 4Completed
- Sponsor
- GW Pharmaceuticals
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in multiple sclerosis (MS) and Muscle spasm comparing Sativex with Placebo (2 arms). Primary endpoint: Change in cognitive function (PASAT total score). Started May 2011; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)Muscle spasm
Beyond the preview
Go deeper on 2011-000926-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000926-31.